News

Novo Nordisk Says Its 'Wegovy In A Pill' Delivers Big: '16.6% Average' Weight Loss, Over 20% For One-Third Of Adults Struggling With Obesity
Novo Nordisk A/S (NYSE: NVO) is seeking FDA approval for the pill version of its obesity drug, Wegovy. The company highlights ...
NBC Bay Area9d
Novo Nordisk opens weight loss drug Wegovy to telehealth; Hims & Hers shares rocket 23%
Hims & Hers started prescribing compounded semaglutide, the active ingredient in Novo Nordisk's diabetes drug Ozempic and Wegovy, in May of 2024. The company has largely had to stop offering the ...
Verywell Health on MSN1d
Wegovy vs. Ozempic: Which Is the Better Weight Loss Drug?
Wegovy and Ozempic are both semaglutide weight loss medications, but they’re prescribed differently based on who qualifies.
Novo Nordisk Q1 Earnings Review: Forget Revenue Miss, Buy Semaglutide Hype
Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...
Telehealth patients get access to more weight-loss drugs
Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Novo Nordisk partners with telehealth ...
Novo Nordisk A/S: ECO 2025 - Novo Nordisk semaglutide data shows new health benefits across serious chronic diseases
Data across obesity, cardiovascular disease, MASH, type 2 diabetes, as well as advances in obesity-related care to be ...
The Economist1d
Eli Lilly looks set to steal Novo Nordisk’s weight-loss crown
Investors are betting that Lilly will maintain its momentum. Its share price has climbed by a third since the start of 2024; ...
NBC New York13d
Novo Nordisk scores major legal win that bars many compounded versions of Wegovy, Ozempic
Eli Lilly’s weight loss pill succeeds in first late-stage trial on diabetes ... permanently prohibiting the business from ...